Children Primary immune thrombocytopenia
Conditions
Interventions
experimental group:Prednisone 1.5-2.0mg/kg/d, divided into 2-3 times, the platelet count is stable for 1-2 weeks, and the dose is gradually reduced to withdrawal, and the course of treatment is 4-6 we
control group:Prednisone 3-4.0mg/kg/d for 4-7 days
Sponsors
Huizhou Municipal Central Hospital
Eligibility
Sex/Gender
All
Age
No minimum to 18 Years
Inclusion criteria
Inclusion criteria: 1. According to the diagnostic criteria in the Diagnosis and Treatment Guidelines for Primary Immune Thrombocytopenia in Children (2019 edition), the diagnosis of primary ITP is definite, excluding secondary ITP and other congenital and tumor thrombocytopenia. Bone marrow examination; 2. Aged 1 month to 18 years; 3. Newly diagnosed ITP, that is, the duration of the disease is less than 3 months; 4. Have not received platelet-enhancing therapy before diagnosis; 5. Obtain consent from the patient and/or guardian.
Exclusion criteria
Exclusion criteria: 1. Concurrent use of other drugs for the treatment of ITP; 2. Have any significant abnormal coexisting disease or mental illness, which affects the life safety and compliance of the child; 3. Cardiopulmonary failure; 4. Those who have a history of allergy to adrenocortical hormones; 5. Patients with diabetes, hypertension, glaucoma, peptic ulcer.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| primary response rate;sustained response rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| bleeding score;response time;Reaction duration; | — |
Countries
China
Contacts
Public ContactLiao Liuhua
Huizhou Municipal Central Hospital
Outcome results
None listed